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Evidence from clinical and experimental studies indicates that hepatitis C virus E2 (HCV/E2) glycoprotein is the major
target of a putatively protective immune response. However, even in the presence of a vigorous production of anti-HCV/E2
antibodies, reinfection can occur. Dissection of the human immune response against HCV/E2 indicated that blocking of
binding of HCV/E2 to target cells [neutralization of binding (NOB) activity] varies widely among antibody clones. Moreover,
in vivo, simultaneous binding of antibodies to distinct epitopes can induce conformational changes and synergies that may
be relevant to understanding the anti-HCV immune response. In this study, human recombinant Fabs were generated by
affinity-selecting a phage display repertoire library with antibody-coated HCV/E2. These Fabs, which share the same
complementarity-determining region DNA sequences, had higher affinity than other anti-HCV/E2 Fabs but showed no NOB
activity even at the highest concentrations. Binding of Fabs to HCV/E2 caused conformational changes modifying Fab-binding
patterns and reducing, with a negative synergistic effect, Fab-mediated NOB activity. These data suggest that some antibody
clones have the potential to modify HCV/E2 conformation and that, in this state, binding of this glycoprotein to its cellular
target is less prone to inhibition by some antibody clones. This can explain why high anti-HCV/E2 antibody titers do not
directly correlate with protection from infection. Information on the interactions among different antibody clones can
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INTRODUCTION
Hepatitis C virus (HCV) is the major cause of blood-
borne non-A non-B hepatitis (Choo et al., 1989; Kuo et al.,
1989). After primary HCV infection, virus persistence oc-
curs in a large proportion of cases (70–80%) and involves
significant risk of progression to liver cirrhosis and hep-
atocellular carcinoma (Alter et al., 1992). Therapy is only
partially effective, with only 20 to 30% long-term response
in patients treated with the current therapy centered on
interferon-a (Fried and Hoofnagle, 1995). In this context,
he development of new therapeutic compounds and the
esign of an effective vaccine have become priorities for
he scientific community.
Currently, the first issue in designing a vaccine is the
recise identification of the viral and host components
nvolved in the elicitation of protective immunity. There is
ow consensus on the existence of HCV-neutralizing
ntibodies based on clinical and experimental data. In
umans, immunoglobulins have proven effective in the
rophylaxis of HCV infection (Piazza et al., 1997). More-
1 To whom reprint requests should be addressed at Istituto di Mi-
robiologia, Facolta` di Medicina e Chirurgia, Universita` di Ancona,2
r
ia Conca, 60020 Ancona, Italy. Fax: 139 071 5964852. E-mail:
.burioni@libero.it.
29ore effective vaccines. © 2001 Academic Press
ver, protection of chimpanzees has been achieved fol-
owing immunization with glycoproteins E1 and E2; this
henomenon has been linked to the induction of specific
nti-E2 antibodies (Choo et al., 1994), commonly referred
o as antibodies with neutralization of binding (NOB)
ctivity, which are able to neutralize the binding of E2 to
usceptible cells. Although the assessment of the capac-
ty of NOB antibodies to inhibit HCV infection has been
ampered by the fact that HCV does not grow efficiently
n cell cultures, high titers of NOB antibodies have been
ssociated with the natural resolution of HCV infection
Ishii et al., 1998). Other studies have failed to demon-
strate a protective effect of these antibodies (Farci et al.,
1992; Lai et al., 1994). This contrasting evidence may
epend on the fact that the antibody response against
lycoprotein E2, a key viral protein that interacts with the
utative cellular receptor CD81 (Pileri et al., 1998), seems
o be highly heterogeneous, at least when assayed by
OB activity. Moreover, recent reports describing the
ynamics of intrahost evolution of HCV populations dur-
ng primary infection have shown that a crucial phase for
isease outcome (i.e., resolution vs persistence) lies at a
ime point corresponding to the production of antibodies
y the infected host (Farci et al., 2000; Manzin et al.,
000). Altogether, these data strongly suggest that the
ole of antibodies in HCV infection, though requiring
0042-6822/01 $35.00
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NI ETfurther study (Cerny and Chisari, 1999), is crucial as may
well be expected of a disease caused by a viral agent
able to finely cope with the immune system for its sur-
vival in the host.
Recently, our group dissected the antibody response
of an HCV-positive patient by generating a large panel of
human monoclonal antibody fragments specific for E2,
demonstrating a remarkable heterogeneity of the clones,
at least when assayed by determination of NOB activity
(Burioni et al., 1998b). However, an important role in vivo
an be played by nonimmunodominant antibodies or by
he simultaneous binding of antibodies to distinct
pitopes, which induces synergies or conformational
hanges. For these reasons, a phage display combina-
orial library containing the antibody repertoire of an
CV-infected patient was affinity-selected using anti-
ody-coated E2 glycoprotein. As a result, genes coding
or a novel family of human recombinant Fabs directed
gainst HCV/E2 glycoprotein were cloned and used for
roduction of human recombinant Fabs in bacteria.
hese Fabs, which failed to be selected with procedures
sing non-antibody-coated antigens despite exhaustive
creening, were characterized with regard to their affinity
nd for their ability to induce conformational antigen
hanges. Moreover, their synergistic effect on the NOB
ctivity of other human recombinant anti-HCV/E2 Fabs
as investigated. The data shown here, revealing in
etail the nature of the humoral immune response
gainst a key HCV antigen, may improve our understand-
ng of the virus–host interplay and may contribute to the
esign of vaccines eliciting more effective responses.
RESULTS
ffinity selection of the phage library and anti-HCV
ab generation
Affinity selection of the phage display combinatorial
ibrary using solid-phase-bound HCV/E2 glycoprotein
oated with purified recombinant anti-E2 human Fabs
ielded a 15-fold enrichment of the eluted phage over
our rounds of panning. Genes coding for putative anti-
CV/E2 were inserted in a soluble Fab expression vector
nd transformed bacteria were used as a source of
ecombinant human Fabs. When analyzed in an ELISA
est using the same antigen used for selection, 12 of 20
lones were demonstrated to react strongly with HCV/
2. Sequence analysis of the heavy chain variable part
ndicated that all the positive clones shared very similar
equences (maximum divergence of 2 nucleotides), al-
owing the grouping of all Fabs into a single family
Burioni et al., 1998b). All complementarity-determining
egions (CDR 1, 2, and 3) were identical in all Fabs. One
f these Fabs, designated HCV/E2 e10B, was chosen,
30 BURIOully sequenced, purified by immunoaffinity, and further
haracterized.The predicted amino acid sequence of the variable
part of the heavy and light chains of Fab e10B, though
corresponding to one expected from a human antibody
variable part, diverged from previously described human
antibodies, confirming its novelty; in particular, the se-
quences were demonstrated to differ from the other Fabs
against HCV/E2 cloned from the same patient (Fig. 1).
Analysis of the sequence over the IMGT database (Le-
franc et al., 1999) demonstrated that the heavy chain was
derived from a VH4 germline and the light chain from a
K1 germline. Both genes showed a mutational pattern
indicating an antigen-driven affinity maturation, as
shown by the lower mutation rate in the framework
region compared with the complementarity-determining
regions (9.5% vs 41.1% in the heavy chain; 6.2% vs 25.5%
in the light chain).
Affinity and competition binding
Relative affinity determinations showed that this Fab
was endowed with a higher affinity than the other Fabs
directed against the same antigen cloned from the same
patient (Fig. 2) and present in the phage library utilized
for affinity selection. Competition binding experiments
demonstrated that, as expected, the binding of Fab e10B
to HCV/E2 is not inhibited by any other Fab (Fig. 3A). In
contrast, previous binding of Fab e10B inhibited the bind-
ing of Fab e8 to HCV/E2 (Fig. 3B). This effect was asym-
metric, as e10B inhibited e8 but was not itself inhibited.
Reciprocal interactions between Fabs were also eval-
uated with soluble HCV/E2 in a sandwich ELISA with the
competing Fab bound to solid support. HCV/E2 bound on
any of the Fabs was accessible by FLAG-labeled e10B,
as expected (data not shown). Binding of HCV/E2 to
bound Fab e10B inhibited subsequent e8 and e10B bind-
ing, while having no effect on binding of e20, e137, e301,
and e509 (Fig. 4).
Neutralization of binding activity and epitope mapping
Measurement of the NOB activity of the e10B clone
showed that, despite its very high affinity, this Fab does
not neutralize the binding of E2 to its cellular target even
at the highest concentration used in our assay (40 mg/
ml). In addition, the binding of this Fab to HCV/E2 de-
creased by 10 times the NOB activity of the most potent
anti-HCV/E2 Fab available (e509), as shown in Fig. 5.
Finally, epitope mapping of the region recognized by Fab
e10B was carried out by pepscan analysis (Burioni et al.,
1998b). The mapping was unsuccessful (data not
shown), suggesting that this antibody fragment recog-
nizes a conformational epitope not reproduced by this
approach.
DISCUSSION
AL.The use of combinatorial libraries displayed on the
surface of filamentous phage containing the immune
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3 NI ETrepertoire of infected patients provides an efficient tool
for dissecting accurately the host response to important
viral antigens. However, certain epitope specificities may
be missed because they are nonimmunodominant or
because they become exposed only in particular situa-
tions, e.g., following conformational changes of the anti-
genic structure. In vivo, antigen exposure does not con-
ist of the sole contact of the native viral antigen with the
mmune system, but also involves the simultaneous
FIG. 2. Determination of relative affinity, estimated by inhibition
ELISA. Data are expressed as a percentage of maximum OD450.
FIG. 3. (A) Inhibition of binding of FLAG–Fab e10B to the antigen by
different concentrations of purified unlabeled Fabs. (B) Inhibition of
binding of different FLAG–Fabs by previous binding of Fab e10B.
2 BURIOBinding of the FLAG–Fabs was demonstrated by FLAG ELISA. Data are
presented as a percentage of inhibition.binding of several antibodies to distinct epitopes, result-
ing in conformational changes and synergies among
different clones representing discrete parts of the hu-
moral immune response. Moreover, structural modifica-
tions induced by the binding of viral surface proteins
to antibodies or receptors can be crucial for viral
physiology and for the development of a protective host
response.
This work indicates how the binding of human recom-
binant Fabs to HCV/E2 glycoprotein can unveil epitopes
that would be inaccessible without this strategy despite
the exhaustive screening of hundreds of different clones
from the library representing the humoral repertoire of an
HCV-infected patient. Previous coating of HCV/E2 with
specific human Fabs allowed the molecular cloning of a
novel family of human recombinant Fabs recognizing a
discrete epitope and representing a part of the antibody
response against HCV/E2 of this infected patient.
The epitope masking procedure may allow the cloning
of human recombinant Fabs directed against weakly
immunogenic epitopes (Ditzel et al., 1995) that elicit an-
tibodies with a lower affinity. This does not seem to be
the case in this work, as measurement of the relative
affinity of Fab e10B showed higher values than with other
Fabs. The difficulties met when isolating phage bearing
FIG. 4. Binding of different FLAG–Fabs to HCV/E2 bound to e10B.
Binding of FLAG–Fab was demonstrated by FLAG ELISA.
FIG. 5. Inhibition of binding of HCV/E2 to its cellular target by
AL.different Fabs. Fab C33-3 is an anti-HCV human Fab directed against
NS3 protein (Plaisant et al., 1997) used as a negative control.
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ING ACthis Fab without using antibody-coated HCV/E2 can be
explained with a relatively low representation of this
particular clone in the repertoire library. Less frequent
clones may miss access to the target protein during the
selection procedure even when endowed with equal or
higher affinity; this phenomenon is usually due to satu-
ration by more frequent clones (Ditzel et al., 1995). Com-
petition experiments showed that the presence of other
anti-HCV/E2 Fabs did not affect the binding of Fab e10B,
as expected considering the strategy by which the mol-
ecule was cloned. However, when Fab e10B was al-
lowed to bind to HCV/E2 before the binding of the other
Fabs was assayed, one of them (e8) could no longer bind
to the antigen. Asymmetric inhibition (e10B inhibiting e8
binding and not vice versa) strongly supports the hypoth-
esis that e10B is directed against a conformationally
modified E2 that fails to be recognized by e8.
The study of the activity of Fab e10B in neutralizing the
binding of E2 to cells by NOB measurement yielded
negative results despite vigorous binding of the Fab to
the antigen even at low concentrations and despite a
relatively high affinity, suggesting that e10B recognizes a
discrete region of E2 not directly involved in binding to
the E2 cellular target. However, the NOB effect of the
binding of Fab e10B is far from negligible, as its pres-
ence considerably reduced the activity of the Fab with
the highest NOB effect described in our previous works
(Burioni et al., 1998b). Demonstration of lack of compe-
ition for binding to the antigen between Fab e509 and
ab e10B using soluble HCV/E2 ruled out the possibility
hat this effect might be due to competition between
hese two Fabs for binding to HCV/E2 in solution.
These data have an important role in the dissection of
he anti-HCV/E2 response at the molecular level and in
nderstanding the effects of the different components of
he humoral immune response against this viral patho-
en. Indeed, the presence of antibodies that, despite
heir high affinity, not only have no effect in neutralizing
he binding of E2 to the cellular target, but considerably
mpair the NOB activity of other molecules, can explain
he lack of NOB effect even in human sera with high
iters against HCV/E2 (Rosa et al., 1996). Furthermore,
the identification of antibodies with these properties in
the humoral repertoire of chronically infected patients
can be crucial to understanding the reinfections that
occur even in the presence of a vigorous immune re-
sponse (Farci et al., 1994; Lai et al., 1994).
Although many attempts have been made to set up
HCV in vitro neutralization tests (Shimizu et al., 1994;
Zibert et al., 1995), this pathogen does not yet grow
reproducibly and efficiently in cell cultures. At present,
the only quantitative method available for measuring
possible antiviral activity is NOB titer determination, even
though its correlation with true neutralization activity re-
MODULATION OF INHIBITION OF BINDmains to be proved, considering that for other viral patho-
gens inhibition of binding to cellular receptors does not
(
Fcorrelate directly with neutralization (Barbas et al.,
1992a).
Finally, this work suggests that E2 is present in at least
two conformational states, only one of which is recog-
nized by Fab e8. It may be speculated that binding of
e10B induces the conformational change. The availability
of antibodies able to distinguish between the two hypo-
thetical states of HCV/E2 can be crucial in shedding light
on the interactions between viral and cellular structures,
which could be at the basis of virus adsorption and entry.
In conclusion, the availability of a panel of Fabs rep-
resenting the interactions of the human humoral immune
system with HCV can be very useful for elucidating the
efficacy of the immune response in protecting against
this infection and for designing new strategies for immu-
nization against HCV. Ideally, these vaccines should be
able to elicit only neutralizing antibodies, avoiding the
production of other nonprotecting immunoglobulins. Ex-
perience with other viral infections that, like HCV, be-
come persistent despite the presence of a detectable
antibody response (as is the case of HIV) suggests that
protective antibodies are indeed generated, but that they
are only a part of the immune response and are probably
produced at a level insufficient to afford protection (Bur-
ton and Parren, 2000).
MATERIALS AND METHODS
Library construction and selection of antigen-binding
phage through library panning
The construction of a phage display library containing
the IgG1/k antibody repertoire of a patient positive for
CV antibodies and HCV RNA in the serum (genotype
b) (Okamoto et al., 1992) has been described previously
Burioni et al., 1998b). Panning of the library without
pitope masking was conducted as described previ-
usly. In brief, four ELISA wells (Costar, Corning, NY)
ere coated overnight with 400 ng/well of HCV (geno-
ype 1a) glycoprotein E2 (Lesniewski et al., 1995). Sub-
equently, plates were washed four times with water and
locked with PBS/3% BSA for 1 h at 37°C. The blocking
olution was discarded, and 50 ml of phage resuspended
n PBS/1% BSA was added to each well and incubated
or 2 h at 37°C. Unbound phage were removed by wash-
ng carefully 10 times with PBS containing 0.5% Tween
0. Bound phage, bearing on the surface antigen-binding
abs, were eluted with acid and amplified, as described,
y Escherichia coli XL-1 Blue (Stratagene, La Jolla, CA)
nfection and with VCS-M13 helper phage (Stratagene)
uperinfection. After four cycles of panning, the pComb3
hage display vector was transformed into pComb3/CAF
oluble Fab expression vector (Burioni et al., 1998a) and
ransformed E. coli were used as a source of Fabs, which
ere produced, purified, and quantified as described
33TIVITY OF ANTI-HCV/E2 HUMAN FabsBarbas et al., 1992b; Ditzel et al., 1995). For production of
LAG-labeled Fab, genes were inserted in the pComb3/
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NI ETFLAG vector (R. Burioni, submitted for publication), with
an epitope added in the carboxy-terminal end of the
heavy chain fragment recognized specifically by a mouse
anti-FLAG monoclonal antibody.
Epitope masking panning procedure
Epitope masking panning was performed as de-
scribed (Ditzel et al., 1995) with some modifications. In
brief, after the well was blocked with PBS/3% BSA, 70 ml
f a mixture containing previously described (Burioni et
l., 1998b) purified human monoclonal recombinant anti-
CV/E2 Fabs e8, e20, e137, e301, and e509 (10 mg/ml
each clone) was added to wells and incubated for 1 h at
37°C. After incubation, 50 ml of the mixture was removed
nd 50 ml of phage was added, incubated, washed,
luted, and amplified as above.
LISA and competition ELISA analyses of
ecombinant Fabs
The reciprocal interactions among different Fabs were
efined by inhibition ELISA. Briefly, antigen-coated plates
ere blocked and 50 ml of a purified preparation of
ompeting Fabs at known concentration was added to
he wells and incubated for 2 h at 37°C. After this step,
n appropriate amount of probe FLAG-labeled purified
ecombinant Fab (FLAG–Fab) was added directly to
ells to obtain a final concentration that gave approxi-
ately 70% of the maximum OD450 (optical density mea-
sured at 450 nm) in ELISA and was incubated for an
additional 30 min. Plates were then washed 10 times
with PBS/0.05% Tween and binding of the FLAG–Fab
probe to the antigen was revealed with anti-FLAG M2
mouse monoclonal antibody (Sigma, St. Louis, MO; 10
mg/ml in PBS). Plates were washed as described above
and binding of mouse monoclonal antibody was demon-
strated by addition of peroxidase-conjugated anti-mouse
antibodies (Sigma; 1:700 in PBS). After a final wash, 100
ml of substrate (Sigma) was added and plates were read
for optical density at 450 nm after 30 min at room tem-
perature in the dark. Final results were determined as a
percentage of inhibition with the formula: percentage
inhibition 5 100 3 (OD450 of probe FLAG–Fab alone 2
D450 of probe FLAG–Fab with competitor Fab)/OD450 of
probe FLAG–Fab alone.
For determination of the reciprocal interactions be-
tween Fabs and HCV/E2 in solution, ELISA plates were
coated with the competing purified Fab at a concentra-
tion of 100 ng/well at 4°C overnight. After washing and
blocking were performed as described above, 40 ml of
HCV/E2 at a concentration of 50 mg/ml in PBS was
added to each Fab-coated well and incubated for 2 h at
37°C. After this step, FLAG–Fabs were added at a con-
centration yielding 70% of the maximum OD in ELISA and
34 BURIOdetermined as described above. Experiments are the
average of three assays performed in duplicate.Relative affinity determination
Determination of relative affinity of purified Fab recom-
binant fragments was performed as described (Burioni et
al., 1998b; Burton et al., 1991; Rath et al., 1988). Briefly,
appropriate amounts of purified Fabs were tested in an
ELISA test in competition with different concentrations of
the same HCV/E2-1a antigen used to coat the plates. Fab
and antigen were added to the plate and incubated for
3 h at 37°C. ELISA was then performed as described
above.
Neutralization of binding assay
Purified preparations of human recombinant Fabs
were tested for their ability to neutralize the binding of
recombinant HCV/E2 glycoprotein to MOLT-4 cells and
50% NOB concentration was determined as described
(Burioni et al., 1998b; Rosa et al., 1996). When two Fabs
were tested together, a mixture of the two molecules (1:1)
was prepared in advance and used for NOB determina-
tions. NOB activity was calculated as the concentration
(in micrograms per milliliter) achieving 50% of neutraliza-
tion of binding. All assays were performed blind at least
in duplicate and repeated twice.
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